Nuclear Medicine Group received DOE Laboratory Technology Research (LTR) funding for restenosis studies

  ORNL Life Sciences Division Nuclear Medicine Nuclear Medicine Group received DOE Laboratory Technology Research (LTR) funding for restenosis studies. ORNL Life Sciences Division Nuclear Medicine Group led by Dr. Russ Knapp has been awarded a three-year DOE LTR contract to evaluate the effectiveness of using rhenium-188 stents for inhibiting coronary restenosis following balloon angioplasty. This effort will be conducted in conjunction with InterDyne, Inc., which has developed a proprietary technique for coating stents with materials which will allow the attachment of rehenium-188. The chemistry will be developed and optimized at ORNL with stents available from InterDyne, and this technology and the required tungsten-rhenium generators will be provided to collaborators at the Brookhaven National Laboratory. Brookhaven in conjunction with the State University at Stonybrook will evaluate the effectiveness of the rhenium-188-coated stents for inhibiting arterial restenosis in swine and rabbit models.

Contact: Russ Knapp
Phone: 574-6225
E-mail: jkp@ornl.gov